Silver Lake Enters Into Exclusive Negotiations to Acquire Groupe Meilleurtaux
22.7.2020 21:49:00 EEST | Business Wire | Press release
Groupe Meilleurtaux (“the Company”), a leading French financial services provider, Silver Lake, a global technology investment firm, and West Street Capital Partners VII (a fund managed by the Goldman Sachs Merchant Banking Division), today announced that they have entered into exclusive negotiations under which Silver Lake would acquire a majority stake in Groupe Meilleurtaux from West Street Capital Partners VII. Management would re-invest in Meilleurtaux alongside Silver Lake.
Hervé Hatt and Guillaume Autier, Chairman and CEO of Groupe Meilleurtaux, said: “We are extremely proud of what Meilleurtaux has achieved over the past three years, with the group’s revenue doubling between 2017 and 2019. Together with our outstanding team, our franchisees, and our partners, we have built a highly successful business with a strong track record of increasing transparency and access to the French financial services ecosystem. As Meilleurtaux begins its new chapter of growth, we are thrilled to welcome Silver Lake, a world-class technology investor with deep financial services and online industry expertise as well as strong value-creation capabilities, as our new majority investor. This investment marks a pivotal step for our company, and we are excited to lead it through this journey.”
Christian Lucas, Co-Head of Silver Lake EMEA, said: “Meilleurtaux is an exceptional company with a unique value proposition across its ecosystem of customers, channel partners and financial providers. We are highly impressed by the way Hervé, Guillaume and the rest of the team have strengthened the business and built it into a multi-channel financial services powerhouse with some 90 million online and mobile visits per year across its various properties. Investing in high-growth, impactful and pioneering business models is at the core of Silver Lake’s DNA, and the privilege of partnering with this management team as Meilleurtaux enters a new phase of growth and value creation is firmly consistent with our mission.”
Michele Titi-Cappelli, Managing Director and Alexandre Flavier, Executive Director of Goldman Sachs, added: “Meilleurtaux is an outstanding platform that plays a pivotal role in democratizing transparency and consumer choice in the French financial services ecosystem. We couldn’t be more pleased with the success of Meilleurtaux under the leadership of Hervé, Guillaume and their team since 2017. We strongly believe that Meilleurtaux is still at the beginning of its growth journey.”
Founded in 1999 and headquartered in Paris, France, Groupe Meilleurtaux provides a broad and diversified range of financial services and products that started historically with mortgage loan comparison and brokerage. Its wide suite of high-quality solutions is seamlessly accessible to consumers through a comprehensive range of leading online and mobile tools including its flagship websites Meilleurtaux.com, Lecomparateurassurance.com and Meilleurplacement.com, as well as financial information website MoneyVox, which in aggregate attract an industry-leading number of approximately 90 million yearly visits. Meilleurtaux.com’s award winning and web-native digital solutions comprise a set of innovative, client-centric toolkits including intuitive financial simulators, calculators and barometers focused solely on helping households save money across their most important financial life decisions on a daily basis. The Company’s unique multi-channel offering is enabled by France’s largest network of 340 brokerage branches, offering customers an unmatched service level in partnership with an industry leading network of more than 300 established bank and insurance providers that together have shaped Meilleurtaux’s trusted brand for over two decades.
Silver Lake is planning to invest heavily in Groupe Meilleurtaux’s product range and partnership network to help further accelerate the Company’s strong organic and inorganic revenue growth across its core business of mortgage and loan insurance brokerage, as well as to further expand its leading offering across the financial services ecosystem. Silver Lake will thereby preserve Groupe Meilleurtaux’s winning operating model while leveraging its capabilities to support management in strengthening it further.
The proposed transaction is expected to close in the fourth quarter and is subject to regulatory approvals and works council information and consultation procedures.
From 1 August 2020 the Meilleurtaux Group’s leadership team will include Guillaume Autier as CEO and Thomas Kienzi as CFO, with Hervé Hatt as chairman of the Board.
About Groupe Meilleurtaux and Meilleurtaux.com
Founded in 1999 and headquartered in Paris, France, Groupe Meilleurtaux is a leading French financial services provider with a broad and diversified range of financial services including loan insurance and mortgage brokerage, debt consolidation solutions, savings & investment products as well as P&C and health insurance distribution and brokerage offerings, available both online and through France’s largest network of 340 brokerage branches. For more information, please visit meilleurtaux.com
About Silver Lake
Silver Lake is a global technology investment firm, with over $40 billion in combined assets under management and committed capital and a team of approximately 100 investment and operating professionals located in Silicon Valley, New York, London and Hong Kong. Silver Lake’s portfolio of investments collectively generates more than $230 billion of revenue annually and employs 370,000 people globally. For more information about Silver Lake and its portfolio, please visit silverlake.com.
About Goldman Sachs Merchant Banking Division
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. Goldman Sachs Merchant Banking Division (MBD) is the primary center for the firm’s long-term principal investing activity. MBD is one of the leading private capital investors in the world with investments across private equity, infrastructure, private debt, growth equity and real estate.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005830/en/
Contact information
Media contacts
FOR SILVER LAKE:
Jennifer Stroud
jennifer.stroud@edelman.com
M: +1-646-565-1792
Virginie Spelle
virginie.spelle@elanedelman.com
M: +33 (0)6 34 03 15 00
FOR GOLDMAN SACHS MERCHANT BANKING DIVISION:
Joseph Stein
+44 20 7774 2523
FOR MEILLEURTAUX.COM:
Anne-Charlotte Neau
anne-charlotte.neau@taddeo.fr
+33(0)6 23 73 56 03
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom